HBEGF抗体;HBEGF Antibody—艾普蒂

+ +

•  

   

     Western blot analysis of HB EGF expression in K562 cell lysate.    

  
  

•  

   

     All lanes use the Antibody at 1:2K dilution for 1 hour at room temperature.    

  
  

Heparin-binding EGF-like growth factor (HBEGF) is a member of the epidermal growth factor (EGF) family that plays critical roles in cell proliferation, migration, and survival. It binds to the EGF receptor (EGFR/ERBB1) and ERBB4. activating downstream signaling pathways such as MAPK and PI3K/AKT. HBEGF is initially synthesized as a transmembrane precursor (proHBEGF) and proteolytically cleaved to release the soluble, bioactive form. It is implicated in diverse physiological and pathological processes, including wound healing, embryonic development, cardiovascular remodeling, and cancer progression. HBEGF overexpression is linked to tumor invasiveness, angiogenesis, and therapy resistance.

HBEGF antibodies are essential tools for detecting and analyzing HBEGF expression and function in research. They enable the identification of HBEGF in tissues or cell lysates via techniques like Western blot, immunohistochemistry, and flow cytometry. Specific antibodies can distinguish between proHBEGF and mature HBEGF, aiding studies on its processing and activation. Additionally, neutralizing HBEGF antibodies are used to inhibit HBEGF-EGFR interactions, providing insights into its mechanistic roles or therapeutic potential. In cancer research, these antibodies help assess HBEGF's contribution to tumor microenvironment signaling and metastasis. Commercial HBEGF antibodies are typically validated for specificity across human, mouse, and rat samples, supporting translational studies. Understanding HBEGF dynamics through antibody-based approaches remains pivotal for exploring its diagnostic or therapeutic relevance in diseases like cancer, fibrosis, and inflammatory disorders.